Emcure Pharmaceuticals Limited has informed the stock exchanges regarding the acquisition of 100% share capital of Cutimed Inc., a Canadian company, by its step-down subsidiary, Mantra Pharma Inc.. Following this acquisition, Cutimed was immediately amalgamated with Mantra Pharma Inc. effective April 01, 2026, to consolidate Canadian operations. This strategic move is designed to strengthen the Group’s dermatological and cosmetic portfolio in Canada.

The acquisition involved a total cash consideration of up to CAD $5.05$ million for the entire equity interest in Cutimed. Cutimed, incorporated in Québec, specializes in cosmetics and personal care products, specifically dermatological creams and cleansers, with an annual turnover of CAD $2.8$ million for the financial year ending August 2025. As the merger occurred between two wholly owned subsidiaries, no additional shares were issued, and the existing shares of Cutimed were cancelled.

Headquartered in Pune, Emcure Pharmaceuticals is a major Indian multinational focusing on a diverse range of therapeutic areas including gynecology, cardiology, oncology, and HIV antivirals. In March 2026, the company signed a significant distribution agreement with Roche to enhance nephrology and transplant care in India. The firm maintains a vertically integrated model with multiple US FDA-approved facilities and has recently in-licensed Lenacapavir from Gilead to reinforce its HIV segment leadership.

For the third quarter of FY 2025-26, the company reported a robust financial performance with revenue reaching ₹2,365.33 Crores. Net profit for this period stood at ₹230.54 Crores, reflecting a significant year-on-year growth of 49.97%. The company’s investor base includes prominent institutional names such as Bain Capital, which acquired a 13% stake from Blackstone in 2014, and various mutual funds like Nippon India and Motilal Oswal which held active positions in 2025.